Collectively, our results suggest that idebenone is a plausible therapeutic molecule for targeting neuroglial NLRP3 inflammasome activation and, in turn, inhibiting the pathological progression of neuroinflammation-related diseases, including AD (Figure 13). Here, NLRP3 is linked to Alzheimer disease.